GRAIL, LLC (GRAL) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $80.77 (+1.03%), Market cap $2.60B, 52-week low–high $31.42 ~ $116.06.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal r
Financial statements, price targets, institutional (13F) holdings and related news for GRAIL, LLC are updated in real time on BlackAll Trade.
GRAIL, LLC trades at $80.77 (+1.03%). Real-time quotes and charts are available on BlackAll Trade.
GRAIL, LLC has a market cap of about $2.60B.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for